← Back to Search

Tyrosine Kinase Inhibitor

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Phase 1 & 2
Waitlist Available
Research Sponsored by Turning Point Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from screening to end of treatment approximately 10 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called repotrectinib, used together with other cancer treatments. It targets patients whose cancers have a specific genetic mutation called KRAS, which makes their cancer harder to treat. The drug works by blocking signals that help cancer cells grow and spread. Repotrectinib is a new drug being tested for its effectiveness in treating cancers with KRAS mutations, which are known to be challenging to treat.

Eligible Conditions
  • KRAS Mutation-Related Tumors
  • Metastatic Tumor
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from screening to end of treatment approximately 10 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from screening to end of treatment approximately 10 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Dose Limiting Toxicities
Secondary study objectives
AUC 0-24 of Repotrecitinib
AUC 0-24 of Trametinib
Cmax of Repotrectinib
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TPX-0005 + TrametinibExperimental Treatment2 Interventions
TPX-0005 + Trametinib Dose Escalation and Dose Expansion Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trametinib
2014
Completed Phase 2
~1630

Find a Location

Who is running the clinical trial?

Turning Point Therapeutics, Inc.Lead Sponsor
9 Previous Clinical Trials
783 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,582 Previous Clinical Trials
3,388,592 Total Patients Enrolled
8 Trials studying Tumors
422 Patients Enrolled for Tumors
Turning Point Therapeutics, MDStudy DirectorTurning Point Theraperutics
3 Previous Clinical Trials
127 Total Patients Enrolled
Turning Point TherapeuticsStudy DirectorTurning Point Theraperutics
~2 spots leftby Dec 2025